Human antibodies that bind human TNF-alpha and methods of preparing the same
US9505833B2 · kind B2 · utility
9Cited by
229References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 12, 2013 |
| Grant date | Nov 29, 2016 |
| Priority date | — |
| Expiry date | Nov 12, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldChemical engineering
- WIPO sectorChemistry
Abstract
Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.